The board of directors SSY Group Limited announced that the group has obtained the approval for drug clinical trial in relation to the bio-equivalency for Cefdinir Capsules from the China Food and Drug Administration. Cefdinir is an anti-infective agent and a type 6 chemical drug.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.29 HKD | 0.00% |
|
-0.92% | -13.16% |
07:48am | Chinese Regulator OKs SSY Group's Betahistine Mesilate Tablets for Drug Production, Registration | MT |
07-05 | Chinese Regulator Approves SSY Group's Several Drugs for Production, Registration | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.16% | 1.63B | |
+63.05% | 856B | |
+38.95% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+13.63% | 244B | |
+4.79% | 234B | |
+16.13% | 226B | |
+14.63% | 177B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development